Takami Sato
Overview
Explore the profile of Takami Sato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
2157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lalonde E, Ewens K, Richards-Yutz J, Ebrahimzedeh J, Mizue Terai , Gonsalves C, et al.
Ophthalmol Sci
. 2022 Oct;
2(2):100121.
PMID: 36249692
Purpose: To evaluate the clinical relevance of low-frequency copy number aberrations (CNAs) in uveal melanoma (UM) and to discern residual genomic and clinical heterogeneity within established molecular subtypes based on...
12.
Carvajal R, Butler M, Shoushtari A, Hassel J, Ikeguchi A, Hernandez-Aya L, et al.
Nat Med
. 2022 Oct;
28(11):2364-2373.
PMID: 36229663
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm,...
13.
Lapadula D, Lam B, Mizue Terai , Sugase T, Tanaka R, Farias E, et al.
Mol Cancer Ther
. 2022 Oct;
22(1):63-74.
PMID: 36223548
Uveal melanoma (UM) is the most common intraocular tumor in adults, and up to 50% of patients develop metastatic disease, which remains uncurable. Because patients with metastatic UM have an...
14.
Wei A, Uriel M, Porcu A, Manos M, Mercurio A, Caplan M, et al.
Front Oncol
. 2022 Oct;
12:961517.
PMID: 36212499
Metastatic uveal melanoma (mUM) is an advanced ocular malignancy characterized by a hepatotropic pattern of spread. As the incidence of brain metastases (BM) in mUM patients has been thought to...
15.
Davar D, Zappasodi R, Wang H, Naik G, Sato T, Bauer T, et al.
Clin Cancer Res
. 2022 May;
28(18):3990-4002.
PMID: 35499569
Purpose: TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor-related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in...
16.
Carvajal R, Nathan P, Sacco J, Orloff M, Hernandez-Aya L, Yang J, et al.
J Clin Oncol
. 2022 Mar;
40(17):1939-1948.
PMID: 35254876
Purpose: This phase I study aimed to define the recommended phase II dose (RP2D) of tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week step-up dosing regimen, and to...
17.
Orloff M, Seedor R, Sato T
Cancer Gene Ther
. 2022 Mar;
29(12):1814-1818.
PMID: 35236927
Uveal melanoma is a rare subtype of melanoma that once metastatic portends a poor prognosis. Likely due to the distinct differences in biology, metastatic potential, and immunologic profile as compared...
18.
Minor D, Kim K, Tong R, Wu M, Kashani-Sabet M, Orloff M, et al.
Cancer Biother Radiopharm
. 2022 Jan;
37(1):11-16.
PMID: 35021863
Liver metastases from uveal melanoma carry a very poor prognosis. Hepatic artery infusions with Yttrium-90 (Y) resin microspheres have some activity in this disease, and radiation and immunotherapy may be...
19.
Mizue Terai , Shimada A, Chervoneva I, Hulse L, Danielson M, Swensen J, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830903
Uveal melanoma is the most common primary ocular malignancy in adults, characterized by gene mutations in G protein subunit alpha q () and G protein subunit alpha 11 (). Although...
20.
Seedor R, Orloff M, Sato T
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771666
Despite successful treatment of primary uveal melanoma, up to 50% of patients will develop systemic metastasis. Metastatic disease portends a poor outcome, and no adjuvant or metastatic therapy has been...